Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Showing 1-25 of 129 citing articles:

Non-small-cell lung cancer
Lizza E.L. Hendriks, Jordi Remón, C. Faivre‐Finn, et al.
Nature Reviews Disease Primers (2024) Vol. 10, Iss. 1
Closed Access | Times Cited: 43
Neoadjuvant and Adjuvant Treatments for Early Stage Resectable NSCLC: Consensus Recommendations From the International Association for the Study of Lung Cancer
Jonathan Spicer, Tina Cascone, Murry W. Wynes, et al.
Journal of Thoracic Oncology (2024) Vol. 19, Iss. 10, pp. 1373-1414
Open Access | Times Cited: 25
Neoadjuvant pembrolizumab plus chemotherapy followed by adjuvant pembrolizumab compared with neoadjuvant chemotherapy alone in patients with early-stage non-small-cell lung cancer (KEYNOTE-671): a randomised, double-blind, placebo-controlled, phase 3 trial
Jonathan Spicer, Marina Chiara Garassino, Heather A. Wakelee, et al.
The Lancet (2024) Vol. 404, Iss. 10459, pp. 1240-1252
Closed Access | Times Cited: 22
Surgical and survival outcomes with perioperative or neoadjuvant immune-checkpoint inhibitors combined with platinum-based chemotherapy in resectable NSCLC: A systematic review and meta-analysis of randomised clinical trials
Daniele Marinelli, Filippo Tommaso Gallina, Sergio Pannunzio, et al.
Critical Reviews in Oncology/Hematology (2023) Vol. 192, pp. 104190-104190
Open Access | Times Cited: 25
New systemic treatment paradigms in resectable non-small cell lung cancer and variations in patient access across Europe
Ilias Houda, Chris Dickhoff, Carin A. Uyl‐de Groot, et al.
The Lancet Regional Health - Europe (2024) Vol. 38, pp. 100840-100840
Open Access | Times Cited: 15
The Emerging Role of Immunotherapy in Resectable Non-Small Cell Lung Cancer
Elizabeth G. Dunne, Cameron N. Fick, James M. Isbell, et al.
The Annals of Thoracic Surgery (2024) Vol. 118, Iss. 1, pp. 119-129
Closed Access | Times Cited: 13
Intrapatient variation in PD-L1 expression and tumor mutational burden and the impact on outcomes to immune checkpoint inhibitor therapy in patients with non-small-cell lung cancer
Alessandro Di Federico, Stephanie Alden, James W. Smithy, et al.
Annals of Oncology (2024) Vol. 35, Iss. 10, pp. 902-913
Closed Access | Times Cited: 10
Toripalimab, a therapeutic monoclonal anti-PD-1 antibody with high binding affinity to PD-1 and enhanced potency to activate human T cells
Narendiran Rajasekaran, Xiaoguang Wang, Sruthi Ravindranathan, et al.
Cancer Immunology Immunotherapy (2024) Vol. 73, Iss. 3
Open Access | Times Cited: 9
Immunotherapy in resectable NSCLC: Answering the question or questioning the answer?
Si‐Yang Liu, Weineng Feng, Yi‐Long Wu
Cancer Cell (2024) Vol. 42, Iss. 5, pp. 727-731
Closed Access | Times Cited: 8
Advancements in the application of ablative therapy and its combination with immunotherapy in anti-cancer therapy
Luhong Wang, Yiyi Jiang, Chaoyue Sun, et al.
Biochimica et Biophysica Acta (BBA) - Reviews on Cancer (2025) Vol. 1880, Iss. 2, pp. 189285-189285
Closed Access | Times Cited: 1
Evolving Paradigms in Lung Cancer: Latest Trends in Diagnosis, Management, and Radiopharmaceuticals
Busra Cangut, Rahman Akinlusi, Ava Mohseny, et al.
Seminars in Nuclear Medicine (2025)
Closed Access | Times Cited: 1
The ASCENT Trial: a phase 2 study of induction and consolidation afatinib and chemoradiation with or without surgery in stage III EGFR-mutant NSCLC
Allison E.B. Chang, Andrew J. Piper-Valillo, Raymond H. Mak, et al.
The Oncologist (2024) Vol. 29, Iss. 7, pp. 609-618
Open Access | Times Cited: 7
Perioperative Immunotherapy for Non-Small Cell Lung Cancer: Practical Application of Emerging Data and New Challenges
Angelica D’Aiello, Brendon M. Stiles, Nitin Ohri, et al.
Clinical Lung Cancer (2024) Vol. 25, Iss. 3, pp. 197-214
Closed Access | Times Cited: 5
Early-Stage Non-Small Cell Lung Cancer: Prevalence of Actionable Alterations in a Monocentric Consecutive Cohort
Rossella Bruno, Anello Marcello Poma, Martina Panozzi, et al.
Cancers (2024) Vol. 16, Iss. 7, pp. 1410-1410
Open Access | Times Cited: 5
Current status and breakthroughs in treating advanced non-small cell lung cancer with EGFR exon 20 insertion mutations
Meng Hu, Congying Zhong, Jiabing Wang, et al.
Frontiers in Immunology (2024) Vol. 15
Open Access | Times Cited: 5
Early-Stage Non-Small Cell Lung Cancer: New Challenges with Immune Checkpoint Blockers and Targeted Therapies
Pernelle Lavaud, Martina Bortolot, Lodovica Zullo, et al.
Cancers (2024) Vol. 16, Iss. 16, pp. 2779-2779
Open Access | Times Cited: 5
High-throughput transcriptome profiling indicates ribosomal RNAs to be associated with resistance to immunotherapy in non-small cell lung cancer (NSCLC)
Myrto Moutafi, Katherine M. Bates, Thazin Nwe Aung, et al.
Journal for ImmunoTherapy of Cancer (2024) Vol. 12, Iss. 6, pp. e009039-e009039
Open Access | Times Cited: 4
Immunotherapy for early-stage non-small cell lung cancer: A practical guide of current controversies
William J. Phillips, Ashley Jackson, Biniam Kidane, et al.
Clinical Lung Cancer (2025)
Open Access
Advances in adjuvant therapy for operable N2 non-small cell lung cancer: a narrative review
Lei Liu, Yan‐Ping Mao, Leilei Guo, et al.
Frontiers in Oncology (2025) Vol. 14
Open Access
Perioperative or neo/adjuvant chemoimmunotherapy versus chemotherapy for resectable non-small cell lung cancer: a systematic review and network meta-analysis
Qiong Zhang, Jia Duan, Yuanmei Zhang, et al.
Systematic Reviews (2025) Vol. 14, Iss. 1
Open Access
Comparison of PD-L1 Expression Between Preoperative Biopsy Specimens and Surgical Specimens in Non-Small Cell Lung Cancer
Tadashi Sakaguchi, Akemi Iketani, Kentaro Ito, et al.
Cancers (2025) Vol. 17, Iss. 3, pp. 398-398
Open Access
Navigating Chemotherapy and Immunotherapy in Early-Stage Lung Cancer. A critical review and statements from INTERACTION group.
Chiara Catania, Claudia Proto, Chiara Bennati, et al.
Critical Reviews in Oncology/Hematology (2025) Vol. 208, pp. 104633-104633
Closed Access
Outcomes of Resectable Locally Advanced Non-Small Cell Lung Cancer After Neoadjuvant Chemoimmunotherapy: A Single Institution Experience
Jose Noy, Alexander Chang, Nelly Chow, et al.
Journal of Clinical Medicine (2025) Vol. 14, Iss. 3, pp. 988-988
Open Access
Postoperative radiotherapy for stage pIIIA-N2 non-small cell lung cancer patients undergoing sublobar resection: A retrospective cohort study
Shoufeng Wang, Xin‐Bin Pan, Wei Huang, et al.
Medicine (2025) Vol. 104, Iss. 6, pp. e41462-e41462
Open Access
Comparative Efficacy of Immunotherapy-based treatment versus Chemotherapy-only in Patients with Unresectable NSCLC with Disease Progression Post Chemoradiation and Durvalumab
Francesco Cortiula, Talia Shentzer Kutiel, Melinda Laine Hsu, et al.
European Journal of Cancer (2025) Vol. 219, pp. 115302-115302
Closed Access
Page 1 - Next Page

Scroll to top